Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-interventional survival follow-up after inotersen trials in familial amyloid polyneuropathy
2017-005115-13Phase 3Active
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2018
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inotersen in familial amyloid polyneuropathy (FAP), sponsored by Ionis Pharmaceuticals. Started Feb 2018; status: active.
02
Drugs
inotersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2017-005115-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005115-13.